In yesterday’s Wall Street session, Bionomics Ltd. ADR (NASDAQ:BNOX) shares traded at $2.70, down -19.88% from the previous session.
BNOX stock price is now 65.98% away from the 50-day moving average and -5.42% away from the 200-day moving average. The market capitalization of the company currently stands at $22.03M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $8, H.C. Wainwright recently Upgraded its rating from Neutral to Buy for Bionomics Ltd. ADR (NASDAQ: BNOX).
There have been several recent changes in the stakes of large investors in BNOX stock. In total, there are 5 active investors with 3.85% ownership of the company’s stock.
On Friday morning Bionomics Ltd. ADR (NASDAQ: BNOX) stock kicked off with the opening price of $3.2000. During the past 12 months, Bionomics Ltd. ADR has had a low of $0.93 and a high of $10.90. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 9.05, and a quick ratio of 9.05. The fifty day moving average price for BNOX is $1.6281 and a two-hundred day moving average price translates $2.7430 for the stock.
The latest earnings results from Bionomics Ltd. ADR (NASDAQ: BNOX) was released for Jun, 2023. The net profit margin was -9031.53% and return on equity was -44.92% for BNOX. For the current quarter, analysts expect BNOX to generate $260k in revenue.
Bionomics Ltd. ADR(BNOX) Company Profile
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company’s lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
